These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Author: Grupo de Hospitales Benazuza.
    Journal: An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095.
    Abstract:
    OBJECTIVE: To assess the hospitalization rate for bronchiolitis in newborns treated with palivizumab in Andalusia. PATIENTS AND METHODS: We performed a prospective study of 283 neonates and infants who received prophylaxis with palivizumab in Andalusia during the 2000-2001 bronchiolitis epidemic. We also performed a descriptive study of hospitalization for bronchiolitis, classifying patients according to gestational age and whether they had bronchopulmonary dysplasia (BPD). RESULTS: Most (86.9 %) of the treated patients were born before week 32 of gestation (63 % before week 30) and 38.4 % developed BPD. A total of 10.6 % of palivizumab-treated newborns were hospitalized for bronchiolitis, of which 3.9 % was caused by respiratory syncytial virus (RSV) (4.8 % of patients with BDP and 3.5 % of those without BPD were RSV-positive). Compared with preterm neonates born in weeks 31 or 32 of gestation, palivizumab-treated newborns born before week 31 showed a higher hospitalization rate for bronchiolitis (13.3 % vs 6.3 %; p < 0.05) and that for RSV was three times higher (5.0 % vs 1.6 %; p < 0.05). Age at admission was 5.8 3.2 months. Length of hospital stay was shorter in RSV-positive patients with bronchiolitis (6.7 vs 7.6 days; p > 0.10). Admission to the intensive care unit was required in 0.7 % of patients and in 50 % of those who were RSV-positive. Adverse effects were observed in 5.1 % of palivizumab-treated patients. CONCLUSION: The marked differences in the perinatal antecedents of patients receiving immunoprophylaxis may explain the variations in the efficacy of palivizumab reported in available studies.
    [Abstract] [Full Text] [Related] [New Search]